...We Welcome You To The Resverlogix HUB withIn The AGORACOM COMMUNITY!

Free
AGORACOM NEWS FLASH

Dear Agoracom Family,

I want to thank all of you for your patience with us over the past 48 hours and apologize for what was admittedly a botched launch of our new site.

As you can see, we have reverted back to the previous version of the site while we address multiple forum functionality flaws that inexplicably made their way into the launch.

To this end:

1.We have identified 8 fundamental but easily fixable flaws that will be corrected in the coming week, so that you can continue to use the forums exactly as you've been accustomed to.

2.Additionally we will also be implementing a couple of design improvements to "tighten up" the look and feel of the forums.

Sincerely,

George et al

Message: What are the biggest hints that BETonMACE will be a huge success,..
Reply New Message
Prev Message Back To Forum Threaded View Next Message

Very few of the "hard" 3-point MACE (cardio death, non-fatal MI, non-fatal stroke) occurred in those trials. 3-point MACE is the primary outcome of BETonMACE.

You state there were VERY FEW 3-point MACE events that occurred n the Phase 2,..

I would have thought the company would have done a trial using the 5-point MACE instead of the 3-point MACE just to be more sure of the outcome. That's a big, long, and expensive trial to do based on something that you did not test before in a smaller phase.

Why do you think they chose to take that risk,..?

Is there no market for the great 5-point MACE results,..or are there other drugs already out there that do the job with 5-point MACE,...?

Is there any chance they might have seen something positive that convinced them that the results for 3-point MACE would be just about as good,...?

 

 

 

 

 

1 Recommendations
Reply New Message
Prev Message Back To Forum Threaded View Next Message
Share
Share
New Message
Please login to post a reply